Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Personalis ( (PSNL) ) has issued an announcement.
On May 12, 2026, Personalis, Inc. held its 2026 annual meeting of stockholders virtually, with 87.76% of outstanding shares represented, establishing a quorum for corporate decision-making. Stockholders elected two Class I directors, Olivia K. Bloom and Woodrow A. Myers, Jr., M.D., to serve until the 2029 annual meeting, reinforcing board continuity and governance stability.
Investors also ratified the Audit Committee’s selection of BDO USA, P.C. as Personalis’ independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, signaling broad shareholder support for the company’s executive pay and financial oversight framework.
The most recent analyst rating on (PSNL) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Personalis stock, see the PSNL Stock Forecast page.
Spark’s Take on PSNL Stock
According to Spark, TipRanks’ AI Analyst, PSNL is a Neutral.
The score is held down primarily by weak financial performance—shrinking TTM revenue, very low margins, large losses, and continued cash burn—despite a relatively conservative balance sheet. Technicals add pressure with the stock trading below key moving averages and negative MACD. The earnings call provides some offset via reaffirmed guidance, accelerating clinical volume, and reimbursement progress, but near-term margin and cash burn risks remain significant.
To see Spark’s full report on PSNL stock, click here.
More about Personalis
Personalis, Inc. is a genomics company operating in the life sciences and biotechnology sector, focused on providing advanced sequencing and analytics services to support precision medicine, oncology research, and biopharmaceutical development. Its primary customers include biopharma companies, research institutions, and healthcare stakeholders seeking high-complexity genomic data for clinical and translational applications.
Average Trading Volume: 1,739,985
Technical Sentiment Signal: Sell
Current Market Cap: $632.5M
See more insights into PSNL stock on TipRanks’ Stock Analysis page.